Reconstitution of purified GABAA receptors: ligand binding and chloride transporting properties.
GABAA receptors have been solubilized from bovine brain membranes and, following purification by benzodiazepine affinity chromatography, have been reconstituted into phospholipid vesicles. Reconstituted vesicles were about 120 nm in diameter, and, on average, each vesicle contained fewer than one GABAA receptor which was reconstituted in an outside-out orientation. These preparations have been used in parallel studies of radiolabeled ligand binding and chloride flux, the latter being measured by following the fluorescence changes of a chloride-sensitive probe which was trapped within the vesicles at the time of reconstitution. The benzodiazepine [3H]flunitrazepam binds to an apparently homogeneous population of sites in these preparations (Kd of 5 nM) whereas the GABA analogue [3H]muscimol binds to both high- and low-affinity sites (KdS of 10 nM and 0.27 microM). Muscimol stimulated chloride flux with an EC50 of 0.2 microM and, at similar concentrations (EC50 = 0.16 microM), potentiated [3H]flunitrazepam binding, suggesting that occupancy of the low-affinity sites may be important for these effects. Diazepam shifted the dose-response curve for muscimol-stimulated flux to about 4-fold lower concentrations without affecting the maximum response. Diazepam did not, however, alter the equilibrium binding of [3H]muscimol. The purified receptor showed densensitization since flux responses were abolished by prior exposure to muscimol. The competitive antagonist bicuculline and the channel blocker picrotoxin completely inhibited ion flux mediated by 3 microM muscimol with EC50 values of 5.3 and 2.5 microM, respectively. These results are discussed in terms of possible mechanisms for activation, inhibition, and modulation of GABAA receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Dunn
S M
SM
Department of Pharmacology, Faculty of Medicine, University of Alberta, Edmonton, Canada.
Thuynsma
R P
RP
D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D001923:Brain Chemistry; D002417:Cattle; D002712:Chlorides / Q000378:metabolism*; D002846:Chromatography, Affinity; D004305:Dose-Response Relationship, Drug; D017022:Flow Injection Analysis; D005445:Flunitrazepam / Q000378:metabolism*; D008024:Ligands; D008081:Liposomes / Q000378:metabolism; D008565:Membrane Proteins / Q000302:isolation & purification / Q000378:metabolism; D009118:Muscimol / Q000378:metabolism* / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011806:Quinolinium Compounds / Q000737:chemistry; D011963:Receptors, GABA-A / Q000302:isolation & purification* / Q000378:metabolism*
D001640:Bicuculline; D002712:Chlorides; D005445:Flunitrazepam; D008024:Ligands; D008081:Liposomes; D008565:Membrane Proteins; D009118:Muscimol; D010852:Picrotoxin; D011806:Quinolinium Compounds; D011963:Receptors, GABA-A; C085493:N-(ethoxycarbonylmethyl)-6-methoxyquinolinium